ALOXI Drug Patent Profile

When do Aloxi patents expire, and when can generic versions of Aloxi launch?

Aloxi is a drug marketed by Helsinn Hlthcare and is included in two NDAs.

The generic ingredient in ALOXI is palonosetron hydrochloride. There are twenty-one drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the palonosetron hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Aloxi

A generic version of ALOXI was approved as palonosetron hydrochloride by SANDOZ on October 13^th, 2015.

Summary for ALOXI

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	147
Patent Applications:	4,555
Drug Prices:	Drug price information for ALOXI
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ALOXI
What excipients (inactive ingredients) are in ALOXI?	ALOXI excipients list
DailyMed Link:	ALOXI at DailyMed

See drug prices for ALOXI

Paragraph IV (Patent) Challenges for ALOXI

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ALOXI	Injection	palonosetron hydrochloride	0.05 mg/mL, 1.5 mL and 5 mL vials	021372	3	2011-05-27

US Patents and Regulatory Information for ALOXI

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Helsinn Hlthcare	ALOXI	palonosetron hydrochloride	CAPSULE;ORAL	022233-001	Aug 22, 2008		DISCN	Yes	No
Helsinn Hlthcare	ALOXI	palonosetron hydrochloride	INJECTABLE;INTRAVENOUS	021372-002	Feb 29, 2008		DISCN	Yes	No
Helsinn Hlthcare	ALOXI	palonosetron hydrochloride	INJECTABLE;INTRAVENOUS	021372-001	Jul 25, 2003		DISCN	Yes	No

Expired US Patents for ALOXI

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Helsinn Hlthcare	ALOXI	palonosetron hydrochloride	INJECTABLE;INTRAVENOUS	021372-001	Jul 25, 2003
Helsinn Hlthcare	ALOXI	palonosetron hydrochloride	INJECTABLE;INTRAVENOUS	021372-001	Jul 25, 2003
Helsinn Hlthcare	ALOXI	palonosetron hydrochloride	INJECTABLE;INTRAVENOUS	021372-002	Feb 29, 2008

International Patents for ALOXI

See the table below for patents covering ALOXI around the world.

Country	Patent Number	Title	Estimated Expiration
Portugal	96001	PROCESSO PARA A PREPARACAO DE DERIVADOS DE ISOQUINOLINA CONDENSADA COM UM ANEL CARBOCICLICO
Hungary	907660
Slovenia	1601359

Supplementary Protection Certificates for ALOXI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2785706	LUC00158	Luxembourg		PRODUCT NAME: AKYNZEO - FOSNETUPITANT/PALONOSETRON; AUTHORISATION NUMBER AND DATE: EU/1/15/1001 20200318
0430190	CA 2005 00023	Denmark
2785706	2020C/516	Belgium		PRODUCT NAME: AKYNZEO - FOSNETUPITANT/PALONOSETRON; AUTHORISATION NUMBER AND DATE: EU/1/15/1001 20200318

Market Dynamics and Financial Trajectory for ALOXI (Palonosetron)

Last updated: January 14, 2026

Executive Summary

ALOXI (palonosetron) stands as a prominent antiemetic agent primarily indicated for preventing chemotherapy-induced nausea and vomiting (CINV). Since its FDA approval in 2003, it has carved a significant niche within oncology supportive care. This comprehensive analysis examines ALOXI’s current market landscape, underlying drivers, competitive environment, pricing dynamics, regulatory influences, and future financial prospects.

Introduction and Background

• Drug Name: ALOXI (Palonosetron)
• Therapeutic Class: 5-HT3 receptor antagonist
• Indications: Prevention of acute and delayed CINV in patients receiving chemotherapy
• Regulatory Milestones: FDA approval in August 2003 (FDA, 2003)

Palonosetron distinguishes itself with a longer half-life (about 40 hours) compared to earlier agents like ondansetron, resulting in sustained antiemetic activity.

Market Overview and Current Status

Global Market Size

• The global antiemetics market was valued at approximately $1.7 billion in 2022 and is projected to reach $3.0 billion by 2030, growing at a CAGR of 6.7% (Grand View Research, 2022).
• ALOXI, as a leading agent within this segment, accounts for roughly 35-40% of 5-HT3 antagonist sales globally.

Key Market Segments

Segment	Share (%)	Notes
Hematologic and solid tumor CINV	70	Primary driver across regions
Postoperative nausea and vomiting	30	Secondary indication, smaller but growing

Geographical Breakdown

Region	Market Share (%)	Growth Drivers	Key Trends
North America	45	Established oncology infrastructure	High adoption, reimbursement, and R&D activity
Europe	25	Supportive healthcare policies	Patent expiries affecting pricing
Asia-Pacific	20	Emerging healthcare infrastructure, rising oncology burden	Increasing adoption, local manufacturing capabilities
Rest of World	10	Variable, constrained by access and affordability	Growth potential with economic development

Market Dynamics

Factors Driving Growth

1. Increasing Incidence of Cancer
   The World Health Organization (WHO) reports approximately 19.3 million new cancer cases worldwide in 2020, with steady annual increases. These translate into greater demand for supportive care agents like ALOXI.

2. Advancements in Chemotherapy Protocols
   As oncology treatments evolve, newer regimens necessitate potent antiemetics. Palonosetron's extended efficacy enhances its appeal.

3. Regulatory Approvals and Guidelines
   Recommendations by bodies such as NCCN (National Comprehensive Cancer Network) endorse palonosetron for CINV prophylaxis, fostering prescribing patterns.

4. Shift Toward Serialized and Targeted Therapies
   While targeted therapies may reduce certain side effects, the aggregate chemotherapy use remains high, sustaining demand for antiemetics.

Challenges and Constraints

• Patent Expiry:
  The primary patent for ALOXI expired in 2018 in several regions (e.g., US), prompting generic entry. Generics significantly pressure branded prices.

• Pricing Pressures:
  Governments and payers have pushed for cost reductions, especially in Europe and Asia, impacting margins.

• Competition:
  Several generics of palonosetron, as well as newer antiemetics like NEPA (netupitant/palonosetron), challenge market share.

Competitive Landscape

Player	Market Share (%)	Key Products	Strengths
Heron Therapeutics	60	ALOXI, generic options	Pioneer, extensive R&D
Mylan (now part of Viatris)	20	Generic palonosetron	Cost leadership
Others	20	Other generics and competing agents	Regional strength

Pricing Trends

Year	US Price (per Dose)	European Price (approximate)	Comments
2018	~$150	€120–€140	Pre-generic expiration
2020	~$100–$120	€80–€110	Post-generic entry
2023	~$70–$100	€70–€100	Continued price erosion

Financial Trajectory and Outlook

Historical Revenue Analysis

Year	Global ALOXI Revenue (Million USD)	Notes
2018	~$350	Peak pre-generic, patent expiry
2020	~$250	Generic competition impacts
2022	~$230	Stabilizing with volume, lower price

Projected Revenue Drivers (2023–2030)

Factor	Impact	Predictions
Increased Cancer Incidence	Rising demand	5–8% year-over-year growth in demand
New Formulations and Combinations	Expanding use cases	Entry of fixed-dose combinations, e.g., NEPA
Market Expansion into Emerging Regions	Untapped markets	CAGR of 7–9% in Asia-Pacific, Latin America
Patent and Formulary Dynamics	Price erosion	Continued decline but stabilization due to volume growth

Forecasts (2023–2030)

Year	Estimated Revenue (Million USD)	CAGR (Compound Annual Growth Rate)	Comments
2023	~$200–$220	—	Post-price stabilization
2025	~$240–$260	4–5%	Growing adoption, expanded indications
2030	~$310–$330	~7%	Market maturation with potential premium formulations

Regulatory and Policy Influences

• FDA and EMA Approvals:
  Regulatory endorsements facilitate market access. Recent expansions include approvals for pediatric CINV indication.

• Reimbursement Trends:
  High-cost drugs like ALOXI are increasingly subject to formulary restrictions. However, value-based care initiatives aid reimbursement for highly effective agents.

• Pricing and Patent Policies:
  Policies aimed at reducing drug costs (e.g., in the US via CMS, in Europe through value assessments) influence net revenues.

Comparison with Alternative Agents

Agent	Type	Half-life	Efficacy	Cost	Regulatory Status
Palonosetron (ALOXI)	5-HT3 antagonist	~40 hrs	Highly effective in delayed CINV	High (post-patent)	Approved (2003), generics post-2018
Ondansetron	5-HT3 antagonist	~4 hrs	Standard, effective for acute	Lower	Long-standing, generic available
Granisetron	5-HT3 antagonist	~9 hrs	Similar to ondansetron	Lower	Approved, generic available
Netupitant + Palonosetron (NEPA)	Fixed-dose combo	N/A	Broader antiemetic profile	Variable	Approved, expanding indications

Future Outlook and Growth Opportunities

• Emerging Indications:
  Use in radiation-induced nausea, post-surgical settings, and pediatric populations.

• Innovative Delivery Systems:
  Liposomal formulations or implantable devices could enhance compliance and efficacy.

• Partnerships and Licensing:
  Expansion through licensing agreements with regional generic manufacturers.

• Digital and Real-World Evidence:
  Leveraging data for cost-effectiveness analyses can support formulary inclusion.

Key Risks

• Price Erosion:
  Ongoing generic competition will continue to pressure revenue margins.

• Regulatory Delays:
  Slow approval of new indications or formulations.

• Market Saturation:
  Maturation characterized by stabilization rather than aggressive growth.

• Competitive Alternatives:
  New antiemetics with improved efficacy or fewer side effects.

---

Key Takeaways

• ALOXI remains a leading antiemetic agent with a strong foothold in supportive cancer care, but faces headwinds from generic competition and pricing pressures.

• The global market is expected to grow at a moderate CAGR (~5–7%) through 2030, driven by rising cancer incidence and expanding indications.

• Manufacturers must innovate through combination therapies, improved formulations, and regional expansion to sustain profitability.

• Regulatory policies and payor dynamics will significantly influence pricing strategies and market access.

• Overall, ALOXI’s financial trajectory hinges on balancing volume growth against ongoing generic pressures and evolving treatment guidelines.

---

FAQs

Q1: What are the primary drivers of ALOXI’s market growth?
A1: Rising global cancer incidence, improved adherence to guidelines recommending palonosetron, and expanding indications.

Q2: How does patent expiry impact ALOXI’s revenue?
A2: Patent expiry in 2018 opened markets to generic versions, leading to significant price reductions and margin compression.

Q3: What are competing agents to ALOXI, and how do they compare?
A3: Generic ondansetron, granisetron, and newer combination agents like NEPA. Palonosetron offers longer half-life and better efficacy in delayed CINV.

Q4: What strategic moves can manufacturers leverage to maximize ALOXI’s value?
A4: Developing fixed-dose combinations, exploring new indications, regional expansion, and differentiating through formulation innovations.

Q5: What are the key regulatory considerations affecting ALOXI’s market?
A5: Approvals for new indications, pediatric use, and biosimilar entry can shape competitive dynamics and reimbursement policies.

---

References

1. FDA. (2003). Approval of Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting.
2. Grand View Research. (2022). Anti-Emetics Market Size & Trends.
3. NCCN Guidelines. (2023). Antiemetic Guidelines for Oncology.
4. WHO. (2020). Cancer Statistics.
5. MarketWatch. (2023). Pharmaceutical Industry Pricing Trends.